Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery
NCT ID: NCT06272461
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
50 participants
INTERVENTIONAL
2023-10-01
2026-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
For the IV-Lido group, patients received a loading dose of Lidocaine than a continuous infusion over twenty-four hours.
For the IV-Keta goup, patients received a loading dose of Ketamine than a continuous injection of Ketamine over twenty-four hours.
Plasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Lidocaine on Postoperative Pain and Long-term Survival in Elderly Patients Undergoing Colorectal Surgery
NCT06405776
Intravenous Lidocaine Infusion in the Management of Post-operative Pain in Colorectal Patients
NCT01836614
Impact of Intravenous Lidocaine During Colorectal Surgery on Pain and Immune Functions
NCT03410836
Effect of Perioperative Intravenous Lidocaine Infusion and Magnesium Infusion on the Functional Recovery After General Anesthesia in the Patients Undergoing Thyroid Surgery
NCT02018276
The Anti-inflammatory Effect of Anesthetics in Abdominal Surgery
NCT03821545
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
For the IV-Lido group (n=25), patients received a loading dose of 1.5 mg/kg of Lidocaine than a continuous infusion of 1.5 mg/kg/h over twenty-four hours.
For the IV-Keta goup(n=25), patients received a loading dose of 0.15mg/kg of Ketamine than a continuous injection of 0.15 mg/kg/h of Ketamine over twenty-four hours.
For both groups, plasma concentrations of Interleukin-6(IL-6) were measured preoperatively before anesthetic induction and at twenty-four hour post operatively. Plasma IL-6 concentrations at each point were compared between the groups.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IV-Lido
Intravenous Lidocaine dose loading than continuous infusion
Lidocaine IV
Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
IV-Keta
Intravenous Ketamine dose loading than continuous infusion
Ketamine Injectable Solution
Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine IV
Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
Ketamine Injectable Solution
Intravenous Lidocaine Vs intravenous Ketamine in colorectal surgery for cancer
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* American society of anesthesiologists' (ASA) physical status of I-III.
* Elective open colorectal surgery.
* Patients with contraindications to lidocaine or ketamine.
* Corticosteroid therapy within the last 6 months.
* History of immunosuppressive therapy.
* History of surgery in the last 3 months.
* Personal medical history of inflammatory bowel disease.
* Personal medical history of cardiac arrythmias or conduction disorders.
* Alcohol or drug abuse.
* Chronic use of opioids or benzodiazepines.
Exclusion Criteria
* Duration of surgery longer than 5 hours.
18 Years
90 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Tunis El Manar
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
HibetAllah Ktata
Associate Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
BEN ALI MECHAAL, Professor
Role: PRINCIPAL_INVESTIGATOR
university manar Tunis, Tunisia
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tunisia
Nabeul, , Tunisia
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UTEM ELKI
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.